Latest Balance Sheet News

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Alkane Resources delivered a record quarterly gold equivalent production of 43,663 ounces with strong cash flow, maintaining its full-year guidance amid ongoing exploration success and operational improvements.

Cygnus Metals reports robust high-grade drill results outside its existing resource at the Chibougamau Copper-Gold Project, driving a 29% increase in global resource and advancing economic studies.

Prospect Resources has completed its Phase 2 drilling at the Mumbezhi Copper Project in Zambia, revealing extended copper mineralisation and significant gold by-product potential. The company is well-funded and poised for updated resource estimates in early 2026.

New Murchison Gold Limited delivered a robust December quarter with production exceeding contractual ore sales limits and unveiled high-grade drilling success at the Lydia Gold Prospect, underpinning its growth ambitions.

Atomos Limited has reported a robust Q2 FY26 with a 44% jump in revenue and its second straight EBITDA-positive quarter, signaling a promising turnaround. The company’s strategic product launches and debt reduction efforts underpin an optimistic outlook for the second half of the fiscal year.

Canadian Phosphate Limited has improved its operating cash flow and strengthened its balance sheet through a successful capital raise and asset sale, while advancing key permits and strategic partnerships for its Canadian phosphate projects.

Jindalee Lithium has secured US government approval for its McDermitt Lithium Project’s exploration plan, reported strong drilling results, and extended exclusivity on a US SPAC listing valued at US$500 million.

Assetora Limited has announced a $4 million pro-rata rights issue priced at $0.16 per share, with half the offer underwritten by existing shareholders to strengthen its balance sheet and repay debt.

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Mayfield Group Holdings has acquired a strategic industrial property adjacent to its BE Switchcraft operations, enabling operational synergies and capacity expansion to support a $30 million contract pipeline.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.